BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Riverlane Secures $75M for Quantum Error Correction Technology

by Roman Kasianov   •   Aug. 6, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# AI & Digital   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Riverlane, a company based in Cambridge, UK, has raised $75 million in a Series C funding round to advance its quantum error correction technology. This investment aims to enhance Riverlane's research and development capabilities, addressing a pertinent challenge in quantum computing — high error rates of qubits.

#advertisement
AI in Drug Discovery Report 2025

Riverlane leadership: left to right: Earl Campbell, VP Quantum Science, Rebecca Simmons, Chief Operating Officer, Marco Ghibaudi, VP Engineering, Steve Brierley, Founder & CEO, Glenn Manoff, Chief Marketing Officer, Maria Maragkou, VP Product & Partnerships

Quantum computing, while still primarily theoretical, has attracted substantial financial interest. Riverlane is developing technology to be integrated into quantum computing systems to monitor, predict, and correct errors in qubits, potentially improving the performance and reliability of these systems. Steve Brierley, the founder and CEO of Riverlane, noted:

“Quantum error correction is the critical enabler for the industry’s next huge wave of progress, from today’s small error-prone machines to large and reliable quantum computers that will start a new age of human progress as significant as the digital revolution. Our partners recognise the value in working with Riverlane to deliver a solution that fits their needs - we are building the right product at the right time to seize this opportunity.”

This funding round raises Riverlane's valuation above $400 million, marking it as the first European quantum computing startup to reach a Series C round.

The Series C funding was led by Planet First Partners, with contributions from ETF Partners and Singapore’s EDBI. Existing investors, including Cambridge Innovation Capital, Amadeus Capital Partners, the UK's National Security Strategic Investment Fund, and Altair, also participated.

More about Riverlane: This Company Makes Quantum Computing Actually Useful

Key Product

Riverlane’s key product, Deltaflow, integrates quantum error correction (QEC) chips and hardware with software designed to correct billions of errors per second. This technology aims to significantly enhance the operational capacity of quantum computers, enabling them to perform millions, and eventually trillions, of operations without failure.

The company’s quantum error correction roadmap, published in July, outlines future product developments and strategic objectives. Riverlane collaborates with several notable organizations, including Rigetti Computing, Alice & Bob, QuEra Computing, Infleqtion, Atlantic Quantum, Oakridge National Lab, and the UK's National Quantum Computing Centre.

Riverlane

Topics: AI & Digital   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.